Endothelial-derived complement factor D contributes to endothelial dysfunction in malignant nephrosclerosis via local complement activation.


Journal

Hypertension research : official journal of the Japanese Society of Hypertension
ISSN: 1348-4214
Titre abrégé: Hypertens Res
Pays: England
ID NLM: 9307690

Informations de publication

Date de publication:
07 2023
Historique:
received: 11 06 2022
accepted: 20 03 2023
revised: 24 12 2022
medline: 6 7 2023
pubmed: 16 5 2023
entrez: 15 5 2023
Statut: ppublish

Résumé

Malignant nephrosclerosis is a thrombotic microangiopathy associated with abnormal local activation of the complement alternative pathway (AP). However, the mechanism underlying local AP activation is not fully understood. We hypothesized that complement factor D (CFD) secreted by endothelial cells triggers vascular dysfunction in malignant nephrosclerosis via local complement activation. We investigated the deposition of CFD in human kidney biopsy tissues and the function of endothelial-derived CFD in endothelial cell cultures. Immunofluorescence microscopy and laser microdissection-targeted mass spectrometry revealed significant deposition of CFD in the kidneys of patients with malignant nephrosclerosis. Conditionally immortalized human glomerular endothelial cells (CiGEnCs) continuously expressed and secreted CFD in vitro. CFD knockdown in CiGEnCs by small interfering RNA reduced local complement activation and attenuated the upregulation of intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), von Willebrand factor (VWF), and endothelin-1 (ET-1) induced by Ang II. The expression of CFD in CiGEnCs was significantly higher than that in other types of microvascular endothelial cells. Our findings suggest that (i) glomerular endothelial cells are an important source of local renal CFD, (ii) endothelial-derived CFD can activate the local complement system, and (iii) endothelial-derived CFD mediates endothelial dysfunction, which may play a role in the pathogenesis of malignant nephrosclerosis.

Identifiants

pubmed: 37188751
doi: 10.1038/s41440-023-01300-3
pii: 10.1038/s41440-023-01300-3
pmc: PMC10184087
doi:

Substances chimiques

Complement Factor D EC 3.4.21.46
Complement System Proteins 9007-36-7
Intercellular Adhesion Molecule-1 126547-89-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1759-1770

Informations de copyright

© 2023. The Author(s).

Références

Zhang Y, Yang C, Zhou X, Hu R, Quan S, Zhou Y, et al. Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis. Nephrol Dial Transpl. 2020 (e-pub ahead of print 20201226; https://doi.org/10.1093/ndt/gfaa280 .
Wenzel UO, Bode M, Köhl J, Ehmke H. A pathogenic role of complement in arterial hypertension and hypertensive end organ damage. Am J Physiol Heart Circ Physiol. 2017;312:H349–h354.
pubmed: 27986662 doi: 10.1152/ajpheart.00759.2016
Shantsila A, Lip GYH. Malignant hypertension revisited-does this still exist? Am J Hypertens. 2017;30:543–9.
pubmed: 28200072 doi: 10.1093/ajh/hpx008
Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97.
pubmed: 20720586 pmcid: 2924908 doi: 10.1038/ni.1923
Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part i - molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
pubmed: 26082779 pmcid: 4451739 doi: 10.3389/fimmu.2015.00262
Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:257.
pubmed: 26074922 pmcid: 4443744 doi: 10.3389/fimmu.2015.00257
Bayly-Jones C, Bubeck D, Dunstone MA. The mystery behind membrane insertion: a review of the complement membrane attack complex. Philos Trans R Soc Lond B Biol Sci. 2017;372:20160221.
pubmed: 28630159 pmcid: 5483522 doi: 10.1098/rstb.2016.0221
Kolev M, Le Friec G, Kemper C. Complement-tapping into new sites and effector systems. Nat Rev Immunol. 2014;14:811–20.
pubmed: 25394942 doi: 10.1038/nri3761
Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, et al. Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9. Kidney Int. 1997;52:1570–8.
pubmed: 9407502 doi: 10.1038/ki.1997.487
Timmermans S, Abdul-Hamid MA, Potjewijd J, Theunissen R, Damoiseaux J, Reutelingsperger CP, et al. C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension. J Am Soc Nephrol. 2018;29:2234–43.
pubmed: 29858281 pmcid: 6065094 doi: 10.1681/ASN.2018020184
Larsen CP, Wilson JD, Best-Rocha A, Beggs ML, Hennigar RA. Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy. Mod Pathol. 2018;31:488–94.
pubmed: 29148534 doi: 10.1038/modpathol.2017.154
Timmermans S, Abdul-Hamid MA, Vanderlocht J, Damoiseaux J, Reutelingsperger CP, van Paassen P. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int. 2017;91:1420–5.
pubmed: 28187980 doi: 10.1016/j.kint.2016.12.009
Menendez-Castro C, Cordasic N, Fahlbusch FB, Ekici AB, Kirchner P, Daniel C, et al. RNA sequencing reveals induction of specific renal inflammatory pathways in a rat model of malignant hypertension. J Mol Med. 2021;99:1727–40.
pubmed: 34528115 doi: 10.1007/s00109-021-02133-8
Mathew RO, Nayer A, Asif A. The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. J Am Soc Hypertens. 2016;10:352–9.
pubmed: 26778772 doi: 10.1016/j.jash.2015.12.007
Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676–87.
pubmed: 19846853 doi: 10.1056/NEJMra0902814
Johnson RJ, Nangaku M. Endothelial dysfunction: the secret agent driving kidney disease. J Am Soc Nephrol. 2016;27:3–5.
pubmed: 26038532 doi: 10.1681/ASN.2015050502
Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol. 2017;188:183–94.
pubmed: 28249350 pmcid: 5383442 doi: 10.1111/cei.12952
Liszewski MK, Kolev M, Le Friec G, Leung M, Bertram PG, Fara AF, et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. 2013;39:1143–57.
pubmed: 24315997 pmcid: 3865363 doi: 10.1016/j.immuni.2013.10.018
Mahajan S, Jacob A, Kelkar A, Chang A, McSkimming D, Neelamegham S, et al. Local complement factor H protects kidney endothelial cell structure and function. Kidney Int. 2021;100:824–36.
pubmed: 34139209 doi: 10.1016/j.kint.2021.05.033
Jalal D, Renner B, Laskowski J, Stites E, Cooper J, Valente K, et al. Endothelial microparticles and systemic complement activation in patients with chronic kidney disease. J Am Heart Assoc. 2018;7:e007818.
pubmed: 30006493 pmcid: 6064828 doi: 10.1161/JAHA.117.007818
Stanton CM, Yates JR, den Hollander AI, Seddon JM, Swaroop A, Stambolian D, et al. Complement factor D in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:8828–34.
pubmed: 22003108 pmcid: 3230905 doi: 10.1167/iovs.11-7933
Volanakis JE, Narayana SV. Complement factor D, a novel serine protease. Protein Sci. 1996;5:553–64.
pubmed: 8845746 pmcid: 2143395 doi: 10.1002/pro.5560050401
Miyagawa T, Taniguchi T, Saigusa R, Fukayama M, Takahashi T, Yamashita T, et al. Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis. Rheumatol (Oxf). 2020;59:2005–15.
doi: 10.1093/rheumatology/kez517
Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020;136:2080–9.
pubmed: 32877502 doi: 10.1182/blood.2020008248
Satchell SC, Tasman CH, Singh A, Ni L, Geelen J, von Ruhland CJ, et al. Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int. 2006;69:1633–40.
pubmed: 16557232 doi: 10.1038/sj.ki.5000277
Elangbam CS, Qualls CW Jr, Dahlgren RR. Cell adhesion molecules-update. Vet Pathol. 1997;34:61–73.
pubmed: 9150551 doi: 10.1177/030098589703400113
Chappey O, Wautier MP, Boval B, Wautier JL. Endothelial cells in culture: an experimental model for the study of vascular dysfunctions. Cell Biol Toxicol. 1996;12:199–205.
pubmed: 9034609 doi: 10.1007/BF00438146
Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharm Rep. 2009;61:22–32.
doi: 10.1016/S1734-1140(09)70004-0
Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res. 1997;34:255–65.
pubmed: 9205537 doi: 10.1016/S0008-6363(97)00039-4
Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4:1186–93.
pubmed: 16706957 doi: 10.1111/j.1538-7836.2006.01949.x
Ergul A. Endothelin-1 and diabetic complications: focus on the vasculature. Pharm Res. 2011;63:477–82.
doi: 10.1016/j.phrs.2011.01.012
Abraham D, Dashwood M. Endothelin-role in vascular disease. Rheumatol (Oxf). 2008;47:v23–24.
doi: 10.1093/rheumatology/ken282
Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002;8:582–7.
pubmed: 12042808 doi: 10.1038/nm0602-582
Sacks SH, Zhou W, Andrews PA, Hartley B. Endogenous complement C3 synthesis in immune complex nephritis. Lancet 1993;342:1273–4.
pubmed: 7901586 doi: 10.1016/0140-6736(93)92362-W
Miyazaki M, Abe K, Koji T, Furusu A, Ozono Y, Harada T, et al. Intraglomerular C3 synthesis in human kidney detected by in situ hybridization. J Am Soc Nephrol. 1996;7:2428–33.
pubmed: 8959636 doi: 10.1681/ASN.V7112428
Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J. 2006;20:217–26.
pubmed: 16449793 doi: 10.1096/fj.05-4747com
Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity. 2008;28:425–35.
pubmed: 18328742 pmcid: 2646383 doi: 10.1016/j.immuni.2008.02.001
Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood. 2008;112:1759–66.
pubmed: 18567839 pmcid: 2518884 doi: 10.1182/blood-2008-04-151068
Barnum SR, Niemann MA, Kearney JF, Volanakis JE. Quantitation of complement factor D in human serum by a solid-phase radioimmunoassay. J Immunol Methods. 1984;67:303–9.
pubmed: 6561229 doi: 10.1016/0022-1759(84)90470-8
Zhang Y, Ghiringhelli Borsa N, Shao D, Dopler A, Jones MB, Meyer NC, et al. Factor H autoantibodies and complement-mediated diseases. Front Immunol. 2020;11:607211.
pubmed: 33384694 pmcid: 7770156 doi: 10.3389/fimmu.2020.607211
Schreiber RD, Müller-Eberhard HJ. Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins. J Exp Med. 1978;148:1722–7.
pubmed: 722244 doi: 10.1084/jem.148.6.1722
Verma SK, Molitoris BA. Renal endothelial injury and microvascular dysfunction in acute kidney injury. Semin Nephrol. 2015;35:96–107.
pubmed: 25795503 doi: 10.1016/j.semnephrol.2015.01.010
Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, et al. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol. 2019;15:87–108.
pubmed: 30607032 doi: 10.1038/s41581-018-0098-z
Daniels BS. The role of the glomerular epithelial cell in the maintenance of the glomerular filtration barrier. Am J Nephrol. 1993;13:318–23.
pubmed: 8116684 doi: 10.1159/000168646
Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108:2369–79.
pubmed: 7673356 doi: 10.1242/jcs.108.6.2369
Pollak MR, Quaggin SE, Hoenig MP, Dworkin LD. The glomerulus: the sphere of influence. Clin J Am Soc Nephrol. 2014;9:1461–9.
pubmed: 24875196 pmcid: 4123398 doi: 10.2215/CJN.09400913
Minami T, Muramatsu M, Kume T. Organ/tissue-specific vascular endothelial cell heterogeneity in health and disease. Biol Pharm Bull. 2019;42:1609–19.
pubmed: 31582649 doi: 10.1248/bpb.b19-00531
Naughton MA, Botto M, Carter MJ, Alexander GJ, Goldman JM, Walport MJ. Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans. J Immunol. 1996;156:3051–6.
pubmed: 8609428 doi: 10.4049/jimmunol.156.8.3051
Sartain SE, Turner NA, Moake JL. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem. 2018;293:7195–208.
pubmed: 29555686 pmcid: 5949983 doi: 10.1074/jbc.RA118.002639

Auteurs

Zheng Wang (Z)

Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Zhe Zhang (Z)

Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Yuan Li (Y)

Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Ying Zhang (Y)

Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Min Wei (M)

Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Hui Li (H)

Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Shanzhi Yang (S)

Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Yali Zhou (Y)

Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Xinjin Zhou (X)

Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China. JZhou@pbmlabs.com.
Department of Pathology, Baylor University Medical Center at Dallas, Dallas, TX, USA. JZhou@pbmlabs.com.

Guolan Xing (G)

Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China. xgl@zzu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH